688273 Nanjing Medlander Medical Technology
- 22.17
- +1.46+7.05%
Nanjing Medlander Medical Technology News
Mayland (688273.SH): Net profit in 2023 decreased by 26.19% year on year, plans to pay 10 to 6 yuan
On April 25, Ge Longhui (688273.SH) released its 2023 annual report. During the reporting period, the company achieved operating income of 341 million yuan, a year-on-year decrease of 9.57%; net profit attributable to shareholders of listed companies was 89,817,900 yuan, a year-on-year decrease of 26.19%; net profit attributable to shareholders of listed companies deducted non-recurring profit and loss of 71,5379 million yuan, a year-on-year decrease of 19.43%; basic earnings per share were 0.8982 yuan/share. It is proposed to distribute a cash dividend of 6.00 yuan (tax included) for every 10 shares to all shareholders.
Mayland (688273.SH) reported first-quarter results, net profit of 36.286 million yuan, an increase of 12.04% over the previous year
Melander (688273.SH) released its report for the first quarter of 2024. The company achieved operating income of 1 during the reporting period...
Medlander Medical Technology Buys Back Shares for 31 Million Yuan
Nanjing Medlander Medical Technology (SHA:688273) repurchased around 1 million shares for 30.9 million yuan, according to the company's filing on the Shanghai Stock Exchange. Each share amounted to be
Mayland (688273.SH): cumulative repurchase of 1.0356% of the company's shares
Glonghui, April 18, 丨 Melande (688273.SH) announced that as of April 17, 2024, the company had repurchased 1,042,000 shares of the company's shares through centralized bidding transactions, accounting for 1.0356% of the company's total share capital of 100,620,000 shares, an increase of 0.0418% compared with the previous disclosure. The highest price of the repurchase transaction was 34.44 yuan/share, and the lowest price was 19.32 yuan/share. The total amount of capital paid was RMB 30,858,192.95 (not included) Transactions such as stamp duty, transaction commissions, etc.
The Market Lifts Nanjing Medlander Medical Technology Co.,Ltd. (SHSE:688273) Shares 29% But It Can Do More
Nanjing Medlander Medical Technology Co.,Ltd. (SHSE:688273) shareholders are no doubt pleased to see that the share price has bounced 29% in the last month, although it is still struggling to make up
Mayland (688273.SH): Cumulative repurchases of 999,900 shares
Gelonghui (688273.SH) announced on March 1, 2024, that as of February 29, 2024, the company had repurchased 999,900 shares of the company's shares through centralized bidding transactions, accounting for 0.9937% of the company's total share capital of 100,620,000 shares. The highest price of the repurchase transaction was 34.44 yuan/share, the lowest price was 23.95 yuan/share, and the total amount of capital paid was RMB 30,024,937.38 (excluding transaction fees such as stamp duty and transaction commissions).
Mayland (688273.SH): Net profit in 2023 fell 27.2% year on year
Glonghui, Feb. 23 | Melande (688273.SH) announced the 2023 annual results report. During the reporting period, the company's total revenue was 34,20.23 million yuan, down 9.25% year on year; operating profit was 10,34398 million yuan, down 29.08% year on year; total profit of 10,2.759 million yuan, down 29.57% year on year; net profit attributable to owners of the parent company after deducting non-recurring profit and loss of 65.2965 million yuan , a year-on-year decrease of 26.33
The medical device sector strengthened, and many other stocks such as Melander rose and stopped
Gelonghui, Feb. 8 | Mailand Biotech rose and stopped 20CM, Zhende Medical and Matilda Biotech went up and down, and Yingkang Life, Lanwei Medicine, and Maipu Medical surged more than 10%. According to news, in January 2024, the State Drug Administration approved the registration of a total of 321 medical device products. Among them, there are 247 domestic Class III medical device products, 41 imported Class III medical device products, and 33 Class II medical device products.
Mayland (688273.SH): A total of 999,900 shares have been repurchased as of January 31
Gelonghui, Feb. 1 | Melande (688273.SH) announced that as of January 31, 2024, the company had repurchased 999,900 shares of the company's shares through centralized bidding transactions, accounting for 0.9937% of the company's total share capital of 100,620,000 shares. The highest price of the repurchase transaction was 34.44 yuan/share, the lowest price was 23.95 yuan/share, and the total amount of capital paid was RMB 30,024,937.38 (excluding transaction fees such as stamp duty and transaction commissions).
Are Nanjing Medlander Medical Technology Co.,Ltd.'s (SHSE:688273) Mixed Financials Driving The Negative Sentiment?
Nanjing Medlander Medical TechnologyLtd (SHSE:688273) has had a rough month with its share price down 18%. We, however decided to study the company's financials to determine if they have got anythin
Melander: The household series is still in the cultivation stage, and the sales base is small
Glonghui, January 3 | Melander's recent investor relations record shows that the household series is one of the company's important strategic products. Currently, it is still in the cultivation stage, and the sales base is small, but with the company's layout and technological breakthroughs in the household series in recent years, it has begun to bear fruit, and it is expected that there will be significant growth in the future.
Mayland (688273): Rehabilitation leader for rapid pipeline iteration
Mailand is the first national-level specialized and innovative “little giant” enterprise in the field of pelvic floor and obstetrics and gynecology rehabilitation. It has many independent intellectual property core technologies in electrical stimulation devices. In the early years, the reproductive rehabilitation and sports rehabilitation market, which relied on the pelvic floor to deeply cultivate an advantageous layout, has begun
Mayland (688273.SH): It is expected that 3 new pelvic floor rehabilitation products will be launched in the first quarter of 2024
Gelonghui, January 2丨Melande (688273.SH) Investor Relations Activity Record Sheet shows that the company continues to invest in research and development of new pelvic floor rehabilitation technology and new products to accelerate the launch of new products and the iterative upgrading of old products. It is expected that in the first quarter of 2024, 3 new pelvic floor rehabilitation line products will be launched. (1) Second generation pelvic floor biostimulation feedback instrument. We have integrated multiple physiological indicators into second-generation new products, improved diagnostic efficiency and accuracy, and helped improve the pertinence and effectiveness of subsequent intelligent treatment plans. (2) Pelvic floor ultrasound imaging system. We will launch a new pelvic floor imaging product, which can be obtained in one stop
Mayland (688273.SH): In 2023, the company's reproductive anti-aging series products are currently sold in some medical and aesthetic institutions
Gelonghui, January 2 | Mailand (688273.SH) Investor Relations Activity Record Form shows that the company's hospital customers include level-III hospitals, level-II hospitals, first-level and community clinics, primary hospitals, etc. According to the company's 2023 semi-annual report data, the company's products have been used in about 7,400 hospitals across the country, including 4,100 level-II and above hospitals and 1,200 level-III hospitals. In 2023, the company's reproductive anti-aging series products are currently sold in some medical and aesthetic institutions. In the future, the company will continue to focus on the iteration and expansion of technology and products in medical application scenarios, and continue to integrate the whole
Melander (688273.SH): The household series is one of the company's important strategic products and is still in the cultivation stage
Gelonghui, January 2丨Melande (688273.SH) Investor Relations Activity Record Sheet shows that as a medical device company focusing on women's health and beauty, Melander has always focused on disease resolution. The in-hospital market is the foundation of the company's foothold, and the out-of-hospital market stems from the spillover effects of product power and the extension of full-scenario solutions. The household series is one of the company's important strategic products. Currently, it is still in the cultivation stage, and the sales base is relatively small. However, with the company's home use series layout and technological breakthroughs in recent years, it has begun to show results, and it is expected that there will be significant growth in the future.
Mayland (688273.SH): Accumulated repurchases of 573,800 shares
Gelonghui, January 2, 丨 Melande (688273.SH) announced that as of December 31, 2023, the company had repurchased 573,848 shares of the company's shares through centralized bidding transactions, accounting for 0.5703% of the company's total share capital of 100,620,000 shares. The highest price of the repurchase transaction was 34.44 yuan/share, the lowest price was 29.84 yuan/share, and the total amount of capital paid was RMB 18,462,994.9 (excluding transaction fees such as stamp duty and transaction fees).
Melander (688273.SH): A total of 573,800 shares have been repurchased as of November 30
Gelonghui (688273.SH) announced that as of November 30, 2023, the company has repurchased 573,848 shares of the company's shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.5703% of the company's total share capital of 100,620,000 shares. The maximum price of the repurchase transaction was 34.44 yuan/share, the lowest price was 29.84 yuan/share, and the total capital paid was RMB 18,462,994.9 (excluding tax stamps, transaction fees and other transaction fees).
Melander (688273.SH): It is expected that the reproductive anti-aging product line and exercise rehabilitation product line will maintain 50%-100% growth in the next 1-2 years
Gelonghui November 23丨Melander (688273.SH) Investor Relations Activity Record Form shows that according to the company's investment and plans for new products, it is expected that in the next 1-2 years, the reproductive anti-aging product line and sports rehabilitation product line will continue to grow by 50%-100%.
The Recent 14% Gain Must Have Brightened Senior Key Executive Ruijia Yang's Week, Nanjing Medlander Medical Technology Co.,Ltd.'s (SHSE:688273) Most Bullish Insider
Key Insights Significant insider control over Nanjing Medlander Medical TechnologyLtd implies vested interests in company growth The top 4 shareholders own 58% of the company Institutions own 18%
31 shares received fund research, and Meland received the most attention
On November 9 | November 8, a total of 45 listed companies were surveyed by institutions. According to the type of research institution, the fund participated in the research activities of 31 companies. Among them, 5 or more funds piled up to research 9 companies. Meland received the most attention, with 27 funds participating in the survey; Fengyi Technology and Century Huatong received collective research from 14 and 11 funds respectively.
Analysis
Price Target
No Data
